Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
NUTX vs ADUS vs AMSF vs UHS vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Insurance - Specialty
Medical - Care Facilities
Medical - Care Facilities
NUTX vs ADUS vs AMSF vs UHS vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Care Facilities | Insurance - Specialty | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $801M | $1.81B | $569M | $10.68B | $17.01B |
| Revenue (TTM) | $880M | $1.45B | $325M | $17.76B | $21.45B |
| Net Income (TTM) | $96M | $100M | $46M | $1.52B | $1.70B |
| Gross Margin | 47.5% | 32.5% | 47.6% | 67.6% | 42.8% |
| Operating Margin | 31.4% | 9.8% | 17.8% | 11.5% | 16.1% |
| Forward P/E | 8.7x | 14.1x | 14.4x | 7.3x | 10.9x |
| Total Debt | $351M | $209M | $491K | $5.51B | $13.17B |
| Cash & Equiv. | $186M | $82M | $62M | $138M | $2.88B |
NUTX vs ADUS vs AMSF vs UHS vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Nutex Health, Inc. (NUTX) | 100 | 9.5 | -90.5% |
| Addus HomeCare Corp… (ADUS) | 100 | 115.4 | +15.4% |
| AMERISAFE, Inc. (AMSF) | 100 | 65.4 | -34.6% |
| Universal Health Se… (UHS) | 100 | 139.2 | +39.2% |
| Tenet Healthcare Co… (THC) | 100 | 267.7 | +167.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUTX vs ADUS vs AMSF vs UHS vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NUTX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
- 82.4% revenue growth vs AMSF's 2.6%
- 10.5% ROA vs AMSF's 5.6%, ROIC 38.0% vs 21.9%
ADUS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.58, Low D/E 19.2%, current ratio 1.80x
AMSF carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.23, yield 8.4%
- Beta 0.23, yield 8.4%, current ratio 0.32x
- 14.3% margin vs ADUS's 6.9%
- Beta 0.23 vs NUTX's 2.01, lower leverage
UHS ranks third and is worth considering specifically for value.
- Lower P/E (7.3x vs 14.4x)
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs ADUS's 399.9%
- PEG 0.33 vs ADUS's 0.70
- +27.4% vs AMSF's -29.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 82.4% revenue growth vs AMSF's 2.6% | |
| Value | Lower P/E (7.3x vs 14.4x) | |
| Quality / Margins | 14.3% margin vs ADUS's 6.9% | |
| Stability / Safety | Beta 0.23 vs NUTX's 2.01, lower leverage | |
| Dividends | 8.4% yield, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.4% vs AMSF's -29.2% | |
| Efficiency (ROA) | 10.5% ROA vs AMSF's 5.6%, ROIC 38.0% vs 21.9% |
NUTX vs ADUS vs AMSF vs UHS vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NUTX vs ADUS vs AMSF vs UHS vs THC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NUTX leads in 2 of 6 categories
UHS leads 1 • THC leads 1 • ADUS leads 0 • AMSF leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NUTX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
THC is the larger business by revenue, generating $21.5B annually — 66.1x AMSF's $325M. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to ADUS's 6.9%. On growth, AMSF holds the edge at +10.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $880M | $1.4B | $325M | $17.8B | $21.5B |
| EBITDAEarnings before interest/tax | $297M | $159M | $58M | $2.7B | $4.3B |
| Net IncomeAfter-tax profit | $96M | $100M | $46M | $1.5B | $1.7B |
| Free Cash FlowCash after capex | $270M | $137M | $8M | $894M | $3.3B |
| Gross MarginGross profit ÷ Revenue | +47.5% | +32.5% | +47.6% | +67.6% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +31.4% | +9.8% | +17.8% | +11.5% | +16.1% |
| Net MarginNet income ÷ Revenue | +11.0% | +6.9% | +14.3% | +8.6% | +7.9% |
| FCF MarginFCF ÷ Revenue | +30.7% | +9.5% | +2.5% | +5.0% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +7.7% | +10.3% | +9.6% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +154.7% | +17.2% | -8.5% | +17.7% | +87.6% |
Valuation Metrics
UHS leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 60% valuation discount to ADUS's 18.7x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs ADUS's 0.93x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $801M | $1.8B | $569M | $10.7B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $967M | $1.9B | $508M | $16.0B | $27.3B |
| Trailing P/EPrice ÷ TTM EPS | 12.84x | 18.67x | 12.27x | 7.38x | 12.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.73x | 14.12x | 14.42x | 7.30x | 10.94x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.93x | — | 0.46x | 0.38x |
| EV / EBITDAEnterprise value multiple | 3.27x | 12.52x | 8.53x | 6.14x | 6.34x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 1.28x | 1.80x | 0.61x | 0.80x |
| Price / BookPrice ÷ Book value/share | 2.15x | 1.65x | 2.30x | 1.48x | 1.97x |
| Price / FCFMarket cap ÷ FCF | 3.26x | 17.48x | 63.83x | 12.57x | 6.72x |
Profitability & Efficiency
NUTX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $9 for ADUS. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs UHS's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +22.2% | +9.3% | +9.7% | +20.7% | +19.6% |
| ROA (TTM)Return on assets | +10.5% | +7.0% | +5.6% | +9.8% | +5.7% |
| ROICReturn on invested capital | +38.0% | +8.8% | +21.9% | +12.3% | +13.2% |
| ROCEReturn on capital employed | +43.2% | +10.9% | +16.8% | +16.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.83x | 0.19x | 0.00x | 0.74x | 1.47x |
| Net DebtTotal debt minus cash | $166M | $127M | -$61M | $5.4B | $10.3B |
| Cash & Equiv.Liquid assets | $186M | $82M | $62M | $138M | $2.9B |
| Total DebtShort + long-term debt | $351M | $209M | $491,000 | $5.5B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | 9.13x | 14.45x | — | 10.92x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $224 for NUTX. Over the past 12 months, THC leads with a +27.4% total return vs AMSF's -29.2%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs AMSF's -9.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.2% | -8.7% | -18.3% | -22.3% | -2.7% |
| 1-Year ReturnPast 12 months | +14.6% | -13.4% | -29.2% | -8.2% | +27.4% |
| 3-Year ReturnCumulative with dividends | +74.8% | +16.3% | -24.8% | +20.8% | +178.5% |
| 5-Year ReturnCumulative with dividends | -97.8% | +0.0% | -18.9% | +12.5% | +190.4% |
| 10-Year ReturnCumulative with dividends | -97.8% | +399.9% | +31.8% | +30.8% | +523.4% |
| CAGR (3Y)Annualised 3-year return | +20.5% | +5.2% | -9.1% | +6.5% | +40.7% |
Risk & Volatility
Evenly matched — AMSF and THC each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than NUTX's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 78.5% from its 52-week high vs AMSF's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 0.58x | 0.23x | 0.60x | 0.71x |
| 52-Week HighHighest price in past year | $193.07 | $124.44 | $48.54 | $246.33 | $247.21 |
| 52-Week LowLowest price in past year | $77.21 | $90.89 | $29.42 | $152.33 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +69.7% | +78.2% | +62.4% | +69.2% | +78.5% |
| RSI (14)Momentum oscillator 0–100 | 59.7 | 49.3 | 34.2 | 39.7 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 197K | 236K | 212K | 793K | 1.2M |
Analyst Outlook
Evenly matched — ADUS and AMSF each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NUTX as "Buy", ADUS as "Buy", AMSF as "Buy", UHS as "Hold", THC as "Buy". Consensus price targets imply 52.3% upside for NUTX (target: $205) vs 32.3% for ADUS (target: $129). For income investors, AMSF offers the higher dividend yield at 8.41% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $205.00 | $128.67 | $44.50 | $231.50 | $268.00 |
| # AnalystsCovering analysts | 2 | 15 | 6 | 43 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | +8.4% | +0.5% | — |
| Dividend StreakConsecutive years of raises | 1 | 2 | 0 | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | $2.55 | $0.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | +2.1% | +9.1% | +8.4% |
NUTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). UHS leads in 1 (Valuation Metrics). 2 tied.
NUTX vs ADUS vs AMSF vs UHS vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NUTX or ADUS or AMSF or UHS or THC a better buy right now?
For growth investors, Nutex Health, Inc.
(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus 2. 6% for AMERISAFE, Inc. (AMSF). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NUTX or ADUS or AMSF or UHS or THC?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus Addus HomeCare Corporation at 18. 7x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus Addus HomeCare Corporation's 0. 70x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NUTX or ADUS or AMSF or UHS or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: THC returned +523. 4% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NUTX or ADUS or AMSF or UHS or THC?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 772% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NUTX or ADUS or AMSF or UHS or THC?
By revenue growth (latest reported year), Nutex Health, Inc.
(NUTX) is pulling ahead at 82. 4% versus 2. 6% for AMERISAFE, Inc. (AMSF). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NUTX or ADUS or AMSF or UHS or THC?
AMERISAFE, Inc.
(AMSF) is the more profitable company, earning 14. 9% net margin versus 6. 6% for Tenet Healthcare Corporation — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus 9. 7% for ADUS. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NUTX or ADUS or AMSF or UHS or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus Addus HomeCare Corporation's 0. 70x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 14. 4x for AMERISAFE, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 52. 3% to $205. 00.
08Which pays a better dividend — NUTX or ADUS or AMSF or UHS or THC?
In this comparison, AMSF (8.
4% yield), UHS (0. 5% yield) pay a dividend. NUTX, ADUS, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is NUTX or ADUS or AMSF or UHS or THC better for a retirement portfolio?
For long-horizon retirement investors, AMERISAFE, Inc.
(AMSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), 8. 4% yield). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMSF: +31. 8%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NUTX and ADUS and AMSF and UHS and THC?
These companies operate in different sectors (NUTX (Healthcare) and ADUS (Healthcare) and AMSF (Financial Services) and UHS (Healthcare) and THC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NUTX is a small-cap high-growth stock; ADUS is a small-cap high-growth stock; AMSF is a small-cap deep-value stock; UHS is a mid-cap deep-value stock; THC is a mid-cap deep-value stock. AMSF pays a dividend while NUTX, ADUS, UHS, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.